Cryo Cell International Inc (CCEL) Stock Price Quote, News…

Summary

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Website

www.cryo-cell.com

Location

Oldsmar, FL, US

Phone813 749 2100

Employees74

CEODavid Portnoy

SectorHealthcare

IndustryMedical - Care Facilities

IPO DateApr 4, 1994

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… 366 | | \* | Aytu BioPharma Inc. | 169,000 | 363 | | \*,1 | Jasper Therapeutics Inc. | 833,391 | 351 | | \* | Werewolf Therapeutics Inc. | 873,745 | 314 | | \*,1 | P3 Health Partners Inc. | 28,358 | 306 | | \* | Cryo-Cell International Inc. | 94,688 | 302 | | \* | Retractable Technologies Inc. | 412,203 | 297 | | \* | Estrella Immunopharma Inc. | 268,605 | 279 | | \* | eXoZymes Inc. | 32,643 | 275 | | \*,1 | Celularity Inc. Class A | 455,049 | 2 …
バンガード・インデックス・ファンズCryo Cell International Inc·Interim Report - Semi-Annual Report (2026.01.01-2026.12.31)·30 Sep·29 Sep
… \* | Nephros Inc. | 131,820 | 539 | | \*,1 | PepGen Inc. | 482,711 | 536 | | \* | Curis Inc. | 220,311 | 511 | | \*,1 | Fibrobiologics Inc. | 815,371 | 507 | | \*,1 | Xilio Therapeutics Inc. | 739,563 | 503 | | \*,1 | IGM Biosciences Inc. | 448,609 | 502 | | | Cryo-Cell International Inc. | 96,757 | 502 | | \* | Generation Bio Co. | 1,557,423 | 499 | | \* | MEI Pharma Inc. | 201,106 | 497 | | \*,1 | vTv Therapeutics Inc. Class A | 33,666 | 496 |
バンガード・インデックス・ファンズCryo Cell International Inc·Interim Report - Semi-Annual Report (2025.01.01-2025.12.31)·30 Sep 25·29 Sep 2025
… gular Genomics Systems Inc. | 39,337 | 765 | | \* | Allovir Inc. | 1,771,721 | 744 | | \*,1 | Vivani Medical Inc. | 636,702 | 739 | | \*,1 | BioAtla Inc. | 1,217,064 | 720 | | \*,1 | Ardent Health Partners Inc. | 41,970 | 717 | | \*,1 | Rani Therapeutics Holdings Inc. Class A | 518,702 | 711 | | \*,1 | Cognition Therapeutics Inc. | 1,009,905 | 708 | | | Cryo-Cell International Inc. | 95,611 | 708 | | \* | Xilio Therapeutics Inc. | 739,563 | 706 |
バンガード・インデックス・ファンズCryo Cell International Inc·Annual Report - Annual Securities Report (2024.01.01-2024.12.31)·30 Jun 25·29 Jun 2025

Key Stats

Trading

Px/Chg 1D$4.02 / +0.75%

Prev Close$4.28

% of 52Wk H85.03%

Avg Volume10.01K

Beta0.44

Mkt Cap32.41M

FD Mkt Cap34.35M

Float

Shrs Out/Float8.06M / 4.06M

Short Float0.00%

Days to Cover1.00

Stock Repurchased$0.00

Current Valuation

EV32.59M

EV/EBITDA-31.49

EV/Sales1.40

P/B-1.83

P/S1.39

FCF Yield5.59%

ROE-3.12%

ROA0.91%

Current Ratio0.71

Dividend

Cash$0.15

Yield13.40%

Yield (TTM)13.40%

Estimates

P/E-13.14

Est P/E0.00

Est EPS-0.02

Est PEG0.00

Valuation

Metric	5Yr Avg	Apr '23	Apr '24	Apr '25	Apr '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	33.36	11.06	-6.32	109.80	-6.19	58.44
Price / Sales	1.60	1.01	1.92	1.38	3.70	0.00
Price / Book Value	-6.46	-20.10	-5.45	-3.34	-1.56	-1.83
Price / Free Cash Flow	20.71	-3.57	46.95	18.34	23.94	17.88
ENTERPRISE VALUE METRICS
Enterprise Value	46.4	40.6	70.6	56.5	31.9	32.6
Enterprise Value / Sales	1.89	1.34	2.25	1.77	4.07	0.00
Enterprise Value / EBITDA	6.14	6.10	-6.78	39.72	-8.36	0.00
Enterprise Value / EBIT	11.01	8.38	-5.82	60.17	-7.69	0.00

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Nov '21	Nov '22	Nov '23	Nov '24	Nov '25
INCOME STATEMENT
Revenue	2.2%	28.9	30.3	31.3	32.0	31.6
Gross Income	5%	19.9	21.5	22.9	24.0	24.2
EBITDA	-32.6%	5.3	6.7	-10.4	1.4	1.1
EBIT	—	4.0	4.8	-12.1	0.9	-0.3
Net Income	—	2.1	2.8	-9.5	0.4	-2.4
EPS (Diluted)	—	0.25	0.33	-1.14	0.05	-0.30
BALANCE SHEET
Cash & ST Inv	-20.7%	8.3	1.7	1.0	3.5	3.3
Total Assets	43.7%	60.7	64.9	61.2	64.7	61.7
Total Liabilities	9.2%	56.5	66.4	72.3	77.9	80.3
Total Shareholder Equity	—	4.2	-1.5	-11.0	-13.2	-18.6
CASH FLOW
Net Operating Cash Flow	-8.8%	7.9	8.6	8.9	6.0	5.5
Cap Ex	-57.3%	-7.0	-17.2	-7.6	-3.6	-0.2
Free Cash Flow	52.3%	1.0	-8.6	1.3	2.4	5.2

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		5.21
Basic Shares		8.06
Market Cap		42.0
Diluted Shares		8.07
Fully Diluted Shares Outstanding		8.07
Fully Diluted Market Cap		42.0
+Consolidated Debt		0.6
−In-the-Money Convertible Debt		—
+Capital Leases		-
+Operating Leases		—
−Cash & Equivalents		-1.4
−Short-term Investments		-2.8
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		41.2

Segment data

Revenue

by Products and services

Processing And Storage Fees99%
Public Banking0%
Product0%